News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Stressgen Biotechnologies Corporation (SSB.TO) Completes Corporate Transaction


3/24/2006 10:30:41 AM

VICTORIA, BC, and SAN DIEGO, CA, March 24 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation ("Stressgen") announced today that the corporate reorganization involving Stressgen and 0747036 B.C. Ltd. ("Investor"), an affiliate of Madison Group, a diversified investment firm, has been completed. The transaction was previously announced on January 30, 2006, and securityholder approval for the transaction was announced on March 16, 2006.

About Stressgen Biotechnologies Corporation:

--------------------------------------------

Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the website located at www.stressgen.com.

Stressgen Contact: ------------------ Donna Slade Director, Investor Relations 6055 Lusk Boulevard San Diego, CA USA 92121 Tel: 858/202-4900 Dir: 858/202-4945 Fax: 858/450-6849 dslade@stressgen.com

Stressgen Biotechnologies Corp.

CONTACT: Stressgen: Donna Slade, Director, Investor Relations, 6055 LuskBoulevard, San Diego, CA, USA 92121, Tel: (858) 202-4900, Dir: (858)202-4945, Fax: (858) 450-6849, dslade@stressgen.com


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES